USA: $ 4.9 Billion Acquisition Gilead Buys Cancer Specialist Forty Seven
Gilead Sciences and Forty Seven have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for approximately $ 4.9 billion.
Foster City/USA — The Boards of Directors of Gilead and Forty Seven have unanimously approved the acquisition of Forty Seven by Gilead.
Through the addition of Forty Seven’s investigational lead product candidate, magrolimab, the acquisition is to strengthen Gilead’s immuno-oncology research and development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). The investigational therapy targets CD47, a “do not eat me” signal that allows cancer cells to avoid destruction thereby permitting the patient’s own innate immune system to engulf and eradicate those cancer cells. Forty Seven presented promising results of a Phase 1b study of magrolimab in patients with MDS and AML at the American Society of Hematology meeting in December 2019. Magrolimab has the potential to be a first-in-class therapy.